A Phase 1/2 Dose-Escalation and Randomized, Controlled, Masked Expansion Trial of Intravitreal 4D-150 Gene Therapy in Adults With Neovascular (Wet) Age-Related Macular Degeneration
Latest Information Update: 14 Dec 2025
At a glance
- Drugs 4D-150 (Primary) ; Aflibercept
- Indications Wet age-related macular degeneration
- Focus Adverse reactions
- Acronyms PRISM
- Sponsors 4D Molecular Therapeutics
Most Recent Events
- 06 Nov 2025 According to a 4D Molecular Therapeutics media release, data will be presented in detail at an upcoming scientific conference.
- 06 Nov 2025 Interim results presented in a 4D Molecular Therapeutics media release.
- 24 Jul 2025 According to a 4D Molecular Therapeutics media release, results from this trial will be presented at the 43rd Annual Scientific Meeting of the American Society of Retina Specialists (ASRS) being held in Long Beach, CA, on August 1, 2025 (11:24 - 11:27 a.m. PT), by John A. Wells.